The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of .2.0 ,ug/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two-to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.
Aerobic gram-negative organisms account for 70 to 85% of bacterial infections in neutropenic cancer patients (1) . Although Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa are isolated most often, other gramnegative bacteria, such as Acinetobacter spp., Aeromonas hydrophila, and Pseudomonas spp. other than P. aeruginosa, are being recovered with increasing frequency from this group of patients (3, 6) . S-25930 (6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-lH,5H-benzo-[ij]-quinolizine-2-carboxylic acid) and S-25932 (6,7-dihydro-9-fluoro-8-imidazolyl- The data accumulated with the 450 bacterial isolates tested are shown in Table 1 . Ciprofloxacin was overall the most active quinolone tested; however, for 9 of the 17 species tested, either A-56620 or difloxacin had similar MICs for 50% of isolates (MIC50s) and MIC90s. A-56620, like ciprofloxacin, was highly active against A. hydrophila, Citrobacter spp., E. coli, Enterobacter spp., and Klebsiella spp. Both these agents were active against P. aeruginosa, although ciprofloxacin was far more so. S-25930 was active against Acinetobacter spp. and A. hydrophila, inhibiting all isolates at a concentration of c0.5 ,ug/ml. It also inhibited most members of the family Enterobacteriaceae at .0.5 ,ug/ml, with the exception of Citrobacterfreundii (MIC90, 2.0 ,ug/ml) and Enterobacter aerogenes and K. pneumoniae (MIC%, 1.0 ,ug/ml for each). S-25932 was frequently two-to eightfold less active than S-25930. The antibacterial spectrum of both agents was limited by relatively poor activity against P. aeruginosa and Pseudomonas maltophilia.
Interest in the quinolones has been rekindled in the past several years by the introduction of several new agents with a broad antibacterial spectrum and great in vitro potency (2) . The two new agents evaluated in this study, S-25930 and S-25932, were less active in vitro than agents such as ciprofloxacin and A-56620 against most gram-negative aerobes. They could, however, still be clinically useful compounds if superior pharmacokinetic properties resulting in enhanced levels in blood and tissues can be demonstrated or if they are less toxic than other quinolones. Their usefulness might be limited by relatively poor activity against P. aeruginosa, a frequent pathogen in neutropenic patients. 
